PriceGrabber: Shoppers to spend same on Dad as they did Mom
LOS ANGELES — Most shoppers plan to spend the same amount of money for Father’s Day as they did for Mother’s Day, a new PriceGrabber survey revealed.
Polling 4,450 U.S. online shopping consumers, the survey found that 70% of shoppers plan to show Dad equal love this year, with 57% planning to spend less than $100 on gifts, 21% planning to spend between $100 and $249, 11% planning to spend more than $249 and an additional 11% saying they have no set budget when purchasing Father’s Day gifts this year.
But as more than half (56%) said they will from online stores via their computers — followed by 36% who plan to buy in brick-and-mortar stores and just 2% of survey respondents saying they plan to purchase gifts from an online store via a mobile device — what will motivate consumers to buy a product or service for Dad is free shipping (59%), price cuts (48%), sales (42%) and coupons (36%). Eighteen percent of shoppers said they will not be influenced by retailer tactics.
"Consumers are still budget conscience and will look for deals when Father’s Day shopping this year," PriceGrabber general manager Graham Jones said. "Even though most shoppers plan to spend under $100 on their Dad this year based on our survey data, it’s not surprising to see that retailer tactics such as free shipping, price cuts, sales and coupons will help sweeten the deal when enticing consumers to buy gifts for Dad this holiday."
Bayer gastrointestinal cancer drug extends progression-free survival in trial
WAYNE, N.J. — An experimental drug made by Bayer HealthCare extended the length of time that patients with gastrointestinal tumors survived without their disease getting worse, according to results of a late-stage clinical trial released Monday.
Bayer announced the release of data from the phase-3 "GRID" trial of regorafenib in patients with gastrointestinal stromal tumors, also known as GIST, whose tumors could not be removed through surgery or whose disease had spread to other parts of the body despite prior treatment with Novartis’ Gleevec (imatinib). The trial compared the ability of regorafenib to extend progression-free survival of patients with that of placebo.
According to the results, which the study’s investigators plan to present at the American Society of Clinical Oncology’s 48th annual meeting in Chicago, patients taking the drug experienced progressive-free survival of nearly five months, compared with just under a month among those taking placebo.
Packaged Facts: U.S. chocolate sales reached nearly $20 billion last year
ROCKVILLE, Md. — The U.S. chocolate market continues to grow, according to a new Packaged Facts report.
Calling the market "mature, differentiated and demanding," Packaged Facts said it has projected that the U.S. market for chocolate sold at retail was $19.5 billion in 2011, up 6.6% over the previous year. The research firm said everyday chocolate, seasonal candies and premium chocolate all posted dollar gains for the market, though the sales also were driven in part by price increases implemented to offset rises in raw material and other costs. The main channel for chocolate sales continue to be supermarkets and convenience stores, but natural food stores also have seen gains, particularly in the organic chocolate category.
For the full report, "Chocolate Candy in the U.S.," click here.